tirzepatide sales Eli Lilly Beats Estimates and Boosts Its Guidance as Diabetes Drug Soar Eli Lilly H1 2025: Tirzepatide

Understanding the Safety Concerns of Compounded GLP-1 Therapies The primary concern when evaluating compounded GLP-1 clinical safety is product quality, consistency, and manufacturing oversight

This is an exciting time for our patients, as we are now in an era where multiple effective agents are FDA approved and several more are in late-phase clinical trials

doi:10.1089/whr.2021.0119

[Abstract]2025 Aug 23;16(1):7864

Novo Nordisk said on Tuesday that "lower realised prices linked to investments in market access, amplified by the [most favoured nation] agreement with the US Administration to bring GLP-1s [weight-loss drugs] to more Americans at a lower cost is assumed" in its lower and sales profit guidance

The optional Precision Peptide Genetic Test analyzes 34 Weight Management insights including GIPR rs1800437 a variant associated with differential GLP-1 response drawn from a 150+ insight panel across 14 pathways